Association between NAD(P)H: Quinone oxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 381-386

  Sarbia, Mario ^a   Bitzer, Monika ^b   Siegel, David ^c   Ross, David ^c   Schulz, Wolfgang A ^b   Zotz, Rainer B ^b   Kiel, Sybille ^b   Geddert, Helene ^b   Kandemir, Yasemin ^b   Walter, Alexandra ^b   Willers, Reinhart ^b   Gabbert, Helmut E ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Adenocarcinoma; Carcinogenesis; NQO1 C609T polymorphism; Tumour disposition

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARTICLE; CANCER RISK; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CARCINOMA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS;

ADENOCARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); ODDS RATIO; POINT MUTATION; POLYMORPHISM, GENETIC; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 0142027069     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11430     Document Type: Article

References (29)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
2. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-9.
3. Wijnhoven BPL, Siersema PD, Hop WCJ, van Dekken H, Tilanus HW. Adenocarcinoma of the distal oesophagus and gastric cardia are one clinical entity. Br J Surg 1998;86:529-35.
4. Lagergren J, Bergström R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for oesophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
5. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and the gastric cardia. J Natl Cancer Inst 1997;89:1277-84.
6. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002;12:111-27.
7. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249-60.
8. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
9. Rauth AM, Goldberg Z, Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 1997;9:339-49.
10. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77-97.
11. Long DJ 2nd, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst 2001;93:1166-70.
12. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995;72:555-61.
13. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 1999;96:8150-5.
14. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113-21.
15. Siegel D, Anwar A, Winski SL, Kepa JK, Dowd KL, Ross D. Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. J Mol Pharmacol 2001;59:263-8.
16. Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Dräger BJ, Sies H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-9.
17. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK, Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-9
18. Clairmont A, Sies H, Ramachandran S, Lear JT, Smith AG, Bowers B, Jones PW, Fryer AA, Strange RC. Association of NAD(P)H: quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999;20:1235-40.
19. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF, United Kingdom Childhood Cancer Study Investigators. A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 1999;59:4095-9.
20. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF. Pharoah PP Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002; 62:3052-7.
21. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995;5:199-206.
22. Chen H, Lum A, Seifried A, Wilkens LR, Marchand LL. Association of the NAD(P)H: quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999;59:3045-8.
23. Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, Inc., 2002.
24. Eickelmann P, Schulz WA, Rohde D, Schmitz-Dräger B, Sies H. Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 1994;375:439-45.
25. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H: quinone oxidoreductase in human lung and lung tumours. Clin Cancer Res 1998;4:2065-70.
26. Siegel D, Ross D. Immunodetection of NAD(P)H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Rad Biol Med 2000; 29:246-53.
27. Anwar SS, Siegel D, Kepa JK, Ross D. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:Quinone Oxidoreductase 1. J Biol Chem 2002;277:14060-7.
28. Sampliner RE, The Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
29. Pisani P, Parkin M, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.